TY - JOUR
T1 - Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms
AU - Yu, Jun
AU - Sadakari, Yoshihiko
AU - Shindo, Koji
AU - Suenaga, Masaya
AU - Brant, Aaron
AU - Navarro Almario, Jose Alejandro
AU - Borges, Michael
AU - Barkley, Thomas
AU - Fesharakizadeh, Shahriar
AU - Ford, Madeline
AU - Hruban, Ralph H.
AU - Shin, Eun Ji
AU - Lennon, Anne Marie
AU - Canto, Marcia Irene
AU - Goggins, Michael
N1 - Funding Information:
This work was supported by Susan Wojcicki and Dennis Troper, NIH grants (R01CA176828 and CA62924), the Pancreatic Cancer Action Network, the Lustgarten Foundation for Pancreatic Cancer Research, the Jimmy V Foundation, the Rolfe Pancreatic Cancer Foundation, and Hugh and Rachel Victor.
Funding Information:
Funding This work was supported by Susan Wojcicki and Dennis Troper, NIH grants (R01CA176828 and CA62924), the Pancreatic Cancer Action Network, the Lustgarten Foundation for Pancreatic Cancer Research, the Jimmy V Foundation, the Rolfe Pancreatic Cancer Foundation, and Hugh and Rachel Victor.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2017
Y1 - 2017
N2 - Objective Secretin-stimulated pancreatic juice contains DNA shed from cells lining the pancreatic ducts. Genetic analysis of this fluid May form a test to detect pancreatic ductal neoplasia. Design We employed digital next-generation sequencing (‘digital NGS’) to detect low-abundance mutations in secretin-stimulated juice samples collected from the duodenum of subjects enrolled in Cancer of the Pancreas Screening studies at Johns Hopkins Hospital. For each juice sample, digital NGS necessitated 96 NGS reactions sequencing nine genes. The study population included 115 subjects (53 discovery, 62 validation) (1) with pancreatic ductal adenocarcinoma (PDAC), (2) intraductal papillary mucinous neoplasm (IPMN), (3) controls with non-suspicious pancreata. Results Cases with PDAC and IPMN were more likely to have mutant DNA detected in pancreatic juice than controls (both p 0.0001); mutant DNA concentrations were higher in patients with PDAC than IPMN (p=0.003) or controls (p<0.001). TP53 and/or SMAD4 mutations were commonly detected in juice samples from patients with PDAC and were not detected in controls (p<0.0001); mutant TP53/SMAD4 concentrations could distinguish PDAC from IPMN cases with 32.4% sensitivity, 100% specificity (area under the curve, AUC 0.73, p=0.0002) and controls (AUC 0.82, p<0.0001). Two of four patients who developed pancreatic cancer despite close surveillance had SMAD4/ TP53 mutations from their cancer detected in juice samples collected over 1 year prior to their pancreatic cancer diagnosis when no suspicious pancreatic lesions were detected by imaging. Conclusions The detection in pancreatic juice of mutations important for the progression of low-grade dysplasia to high-grade dysplasia and invasive pancreatic cancer May improve the management of patients undergoing pancreatic screening and surveillance.
AB - Objective Secretin-stimulated pancreatic juice contains DNA shed from cells lining the pancreatic ducts. Genetic analysis of this fluid May form a test to detect pancreatic ductal neoplasia. Design We employed digital next-generation sequencing (‘digital NGS’) to detect low-abundance mutations in secretin-stimulated juice samples collected from the duodenum of subjects enrolled in Cancer of the Pancreas Screening studies at Johns Hopkins Hospital. For each juice sample, digital NGS necessitated 96 NGS reactions sequencing nine genes. The study population included 115 subjects (53 discovery, 62 validation) (1) with pancreatic ductal adenocarcinoma (PDAC), (2) intraductal papillary mucinous neoplasm (IPMN), (3) controls with non-suspicious pancreata. Results Cases with PDAC and IPMN were more likely to have mutant DNA detected in pancreatic juice than controls (both p 0.0001); mutant DNA concentrations were higher in patients with PDAC than IPMN (p=0.003) or controls (p<0.001). TP53 and/or SMAD4 mutations were commonly detected in juice samples from patients with PDAC and were not detected in controls (p<0.0001); mutant TP53/SMAD4 concentrations could distinguish PDAC from IPMN cases with 32.4% sensitivity, 100% specificity (area under the curve, AUC 0.73, p=0.0002) and controls (AUC 0.82, p<0.0001). Two of four patients who developed pancreatic cancer despite close surveillance had SMAD4/ TP53 mutations from their cancer detected in juice samples collected over 1 year prior to their pancreatic cancer diagnosis when no suspicious pancreatic lesions were detected by imaging. Conclusions The detection in pancreatic juice of mutations important for the progression of low-grade dysplasia to high-grade dysplasia and invasive pancreatic cancer May improve the management of patients undergoing pancreatic screening and surveillance.
UR - http://www.scopus.com/inward/record.url?scp=84978698475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978698475&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2015-311166
DO - 10.1136/gutjnl-2015-311166
M3 - Article
C2 - 27432539
AN - SCOPUS:84978698475
SN - 0017-5749
VL - 66
SP - 1677
EP - 1687
JO - Gut
JF - Gut
IS - 9
ER -